<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02601885</url>
  </required_header>
  <id_info>
    <org_study_id>M14-173</org_study_id>
    <nct_id>NCT02601885</nct_id>
  </id_info>
  <brief_title>A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis</brief_title>
  <official_title>An Escalating Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to evaluate the safety, tolerability, pharmacokinetics (PK) and
      immunogenicity of ABT-555 in participants with relapsing forms of multiple sclerosis (RFMS).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 18, 2016</start_date>
  <completion_date type="Actual">April 20, 2018</completion_date>
  <primary_completion_date type="Actual">April 20, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and percentage of participants reporting adverse events</measure>
    <time_frame>Throughout study from Day 1 to Day 176</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of anti-drug antibody (ADA) titers of ABT-555</measure>
    <time_frame>Day 1 to Day 176</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum observed plasma concentration (Tmax) of ABT-555</measure>
    <time_frame>Day 1 to Day 176</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of ABT-555</measure>
    <time_frame>Day 1 to Day 176</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration curve (AUC) of ABT-555</measure>
    <time_frame>Day 1 to Day 176</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who experience relapse and disability progression</measure>
    <time_frame>Throughout the study to Day 176</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion volume of new, newly enlarging T2 hyperintense lesions</measure>
    <time_frame>Throughout study from Day 0 to Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of new, newly-enlarging T2 hyperintense lesions</measure>
    <time_frame>Throughout study from Day 0 to Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of new Gadolinium-enhancing T1 lesions</measure>
    <time_frame>Throughout study from Day 0 to Day 113</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive multiple doses of ABT-555 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive multiple doses of ABT-555 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive multiple doses of ABT-555 or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-555</intervention_name>
    <description>Intravenous Infusion</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>Elezanumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous Infusion</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Currently receiving one of the following MS medications for at least 3 months:
             beta-interferon (any formulation including the pegylated form), glatiramer acetate
             (Copaxone®, others), teriflunomide (Aubagio®), fingolimod (Gilenya®), or dimethyl
             fumarate (Tecfidera®); OR

          -  Has not been treated with an MS immunotherapy for the past 6 months (12 months if they
             previously received cyclophosphamide or alemtuzumab); OR

          -  Treatment naïve with established MS diagnosis per criteria by a neurologist.

          -  Diagnosis of relapsing-remitting MS (RRMS) or secondary progressive MS (SPMS)
             according to revised McDonald criteria

          -  Baseline Expanded Disability Status Scale (EDSS) between 0 and 6.0, inclusive.

          -  Brain MRI scan at Screening that did not show evidence of overt vascular lesions,
             masses, mass effect or other abnormalities other than those compatible with MS, which
             would preclude the participant from undergoing a lumbar puncture/spinal tap for CSF
             collection

        Exclusion Criteria:

          -  Diagnosis of primary progressive MS.

          -  Anticipated maintenance immunomodulator change, either agent or dose

          -  An MS relapse that occurred within the 30 days prior to randomization AND/OR the
             participant has not stabilized from a previous relapse prior to randomization

          -  Participants for whom MRI is contraindicated

          -  Participants who have claustrophobia that cannot be medically managed or are unable to
             lie still for 1 hour or more for the imaging procedures

          -  Findings on brain MRI scan indicating any clinically significant brain abnormality
             other than MS

          -  Contraindication for lumbar puncture
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Compass Research LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rowe Neurology Institute</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parexel International</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MIND</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Univ Med Ctr</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-State Mountain Neurology</name>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <zip>37604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Network</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrated Neurology Services</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <zip>22310</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2015</study_first_submitted>
  <study_first_submitted_qc>November 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2015</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsing-remitting</keyword>
  <keyword>Secondary progressive</keyword>
  <keyword>Relapsing forms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

